Parkinson DiseasePhase 3NCT03877510
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
A Phase 3 study testing IPX203 in people with Parkinson Disease, run by Impax Laboratories, LLC at 98 sites in 8 countries.
Trial summary
The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- IPX203
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 419 participants
- Where
- 98 sitesin 8 countries
- Study dates
- 3 Apr 2019to 21 Mar 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Successfully completed Study IPX203-B16-02
- Able to provide written informed consent prior to the conduct of any study-specific procedures.
- Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit (Visit 1).
- Agrees to use a medically acceptable method of contraception throughout the study and for 6 weeks after completing the study.
Who cannot join
- Intends to use any doses of Rytary® or Duopa™ during this study.
- Plans to use an investigational treatment other than IPX203 during the course of this study.
- Neurosurgical ablation treatment for PD is planned or anticipated during the study period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study.
- Participants who, in the opinion of the clinical investigator, should not participate in the study.
Trial locations and contacts
98 sites in 8 countries.
98 sites in 8 countries
United States50 sites
Albany Medical College (139)
Albany, New York, 12208
Emory Brain Health Center (110)
Atlanta, Georgia, 30329
JEM Research Institute (136)
Atlantis, Florida, 33462
University of Colorado Hospital Anschutz Outpatient Pavilion (120)
Aurora, Colorado, 80045
Visionary Investigators Network (168)
Aventura, Florida, 33180
UHealth at Boca Raton (152)
Boca Raton, Florida, 33431
Parkinson's Disease and Movement Disorders Center of Boca Raton (121)
Boca Raton, Florida, 33486
Northwestern Medical Group Neurology Clinic (145)
Chicago, Illinois, 60611
Ucgni (133)
Cincinnati, Ohio, 45219
University Hospitals Cleveland Medical Center (123)
Cleveland, Ohio, 44106
Cleveland Clinic(144)
Cleveland, Ohio, 44195
Neurology Consultants of Dallas, PA (108)
Dallas, Texas, 75251
University of Texas Southwestern Medical Center (143)
Dallas, Texas, 75390-9184
NeuroStudies.net, LLC (155)
Decatur, Georgia, 30033
Rocky Mountain Movement Disorders (116)
Englewood, Colorado, 80113
Inova Neurology- Fairfax (147)
Fairfax, Virginia, 17601
Quest Research Institute (103)
Farmington Hills, Michigan, 48334
VCU Health- Neuroscience Orthopaedic and Wellness Center(124)
Henrico, Virginia, 23233
Infinity Clinical Research LLC (104)
Hollywood, Florida, 33024
Houston Methodist Neurological Institute/Movement Disorders Clinic (135)
Houston, Texas, 77030
Indiana University Health Neuroscience Center(164)
Indianapolis, Indiana, 46202
University of Florida Health Science Center (129)
Jacksonville, Florida, 32209
University of Kansas Medical Center (118)
Kansas City, Kansas, 66160
Booth Gardner Parkinson's Care Center (112)
Kirkland, Washington, 98034
Roseman Medical Research Institute / Roseman Medical Group (154)
Las Vegas, Nevada, 17601
Cleveland Clinic Lou Ruvo Center for Brain Health (142)
Las Vegas, Nevada, 89106
Clinical Trials, Inc (113)
Little Rock, Arkansas, 72205
University of Arkansas for Medical Sciences (117)
Little Rock, Arkansas, 72205
Keek School of Medicine of USC/ University of Southern California (106)
Los Angeles, California, 90033
Neurology Associates, P.A. (125)
Maitland, Florida, 32751
University of Miami (149)
Miami, Florida, 33136
Medical Professional Clinical Research Center, Inc. (163)
Miami, Florida, 33165
The Vanderbilt Clinic (158)
Nashville, Tennessee, 37232
ChristianaCare Neurology Specialists (153)
Newark, Delaware, 19713
Hoag Memorial Hospital Presbyterian (134)
Newport Beach, California, 92663
SC3 Research-Pasadena (148)
Pasadena, California, 91105
Xenoscience, Inc (102)
Phoenix, Arizona, 85004
St. Joseph's Hospital & Medical Center - Barrow Neurological Institute (156)
Phoenix, Arizona, 85013
Parkinson's Disease Treatment Center of Southwest Florida (131)
Port Charlotte, Florida, 33980
SC3 Research-Reseda (146)
Reseda, California, 91335
Inland Northwest Research (119)
Spokane, Washington, 99202
Washington University (109)
St Louis, Missouri, 63110
Infinity Clinical Research, LLC (105)
Sunrise, Florida, 33351
University of South Florida (114)
Tampa, Florida, 33615
University of Toledo, Gardner-McMaster Parkinson Center (122)
Toledo, Ohio, 43614
The Movement Disorder Clinic of Oklahoma (115)
Tulsa, Oklahoma, 74136
Henry Ford West Bloomfield Hospital(100)
West Bloomfield, Michigan, 48322
Premiere Research Institute at Palm Beach Neurology (174)
West Palm Beach, Florida, 33407
Central DuPage Hospital (151)
Winfield, Illinois, 60190
Charter Research (166)
Winter Park, Florida, 32792
Spain14 sites
Hospital Universitario Quiron Dexeus (501)
Barcelona, 08028
Germanes Hospitalaries Del Sagrat Cor De Jesus Hospital Sant Rafael (516)
Barcelona, 08035
Hospital Universitario Vall d'Hebron (505)
Barcelona, 08035
Hospital de Ia Santa Creu i Sant Pau (502)
Barcelona, 08041
Policlinica Gipuzkoa, S.A (511)
Donostia / San Sebastian, Gipuzkoa, 20014
Hospital General Universitario de Elche (509)
Elche, Alicante, 03203
Hospital Universitario de Ia Princesa (508)
Madrid, 28006
Hospital Universitario Ramon y Cajal (500)
Madrid, 28034
Hospital Universitario Infanta Sofia(513)
Madrid, 28703
Clinica Universidad de Navarra (512)
Pamplona, Navarre, 31008
Hospital Universitari General de Catalunya (504)
Sant Cugat del Vallès, Barcelona, 08195
Hospital Universitario Virgen del Rocio (503)
Seville, 41013
Hospital Universitari Mutua Terrassa (506)
Terrassa, Barcelona, 08222
Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell (515)
Valencia, 46026
Italy8 sites
Centro Ricerca Parkinson San Raffaele Cassino (601)
Cassino, Frosinone, 03043
Department "G. F. Ingrassia" section of neuroscience - Policlinico "Vittorio Emanuele" (608)
Catania, Sicily, 95123
Università G. D'annunzio CeSi Met (604)
Chieti, Italy/Chieti/Abbruzzo, 66100
Fondazione I st ituto Neurologico Nazionale "C. Mondino" (606)
Pavia, Italy/Pavia/Lombardia, 27100
Azienda Ospedaliero-Universitaria Pisana (602)
Pisa, Italy/Pisa/Toscana, 56126
IRCCS San Raffaele Pi sana (600)
Roma, Italy/Roma/Lazio, 00163
Department of neuroscience, mental health and sensory system (NeSMOS), "Sapienza" University (603)
Roma, Italy/Roma/Lazio, 00189
University of Rome Tor Vergata/Hospital Tor Vergata (605)
Rome, Lazio, 00133
Poland7 sites
Centrum Medyczne Neuromed (803)
Bydgoszcz, 85163
Centrum Medyczne Linden (805)
Krakow, 30721
Krakowska Akademia Neurologii Sp. Zo.o.(802)
Krakow, 31-505
NZOZ Neuromed M. i M. Nastaj Sp.p. (800)
Lublin, 20-064
NZOZ Neuro-Kard Ilkowski i Partnerzy Spolka Partnerska Lekarzy (801)
Poznan, 61853
Neuro-Care Sp. z o.o. sp. k. (804)
Siemianowice Śląskie, 41100
Centrum Medycme NeuroProtect (806)
Warsaw, 01-684
Czechia6 sites
Fakultni nemocnice u sv. Anny v Brne, I. neurologicka klinika (704)
Brno, 65691
NEUROHK. s.r.o. (701)
Choceň, 56501
Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Neurologicka klinika (702)
Pardubice, 53203
CLINTRIAL s.r.o. (703)
Prague, 10000
AXON Clinical. s.r.o. (700)
Prague, 15000
Neurologicka ordinace FORBELI s.r.o. (706)
Prague, 16000
Germany6 sites
Kliniken Beelitz GmbH, neurologisches Fachkrankenhaus fur Bewegungsstorungen/Parkinson (300)
Beelitz-Heilstätten, Beelitz, 14547
Dr. med. Reinhardt Ehret Neuroloqie Berlin Schlobstr. 29 (309)
Berlin, 12163
St. Josef-Hospital, Universitatsklinik fur Neurologie Klinisches Forschungszentrum fur Neurodegeneration (301)
Bochum, Gudrunstabe 56, 44791
Klinik Haag i. OB Geriatric Hospital Krankenhausstrabe 4 (305)
Haag in Oberbayern, 83527
Klinikum rechts der lsar der Technischen Universitat Munchen Klinik und Poliklinik fur Neurologie (303)
München, Ismaningerstrabe, 81675
Gemeinschaftspraxis Dr. med. J. Springub/W. Schwarz, Studienzentrum Nordwest (306)
Westerstede, 26655
France4 sites
CHU de Clermont-Ferrand-Hopital Gabriel Montpied (404)
Clermont-Ferrand, 63003
CHU de Montpellier, Hopital Gui de Chauliac (405)
Montpellier, 34295
Centre Hospitalier Universitaire de Nice (400)
Nice, 06002
Centre d'lnvestigation Clinique 1436- CHU Purpan- Hopital Pierre Paul Riquet (403)
Toulouse, 31059
United Kingdom3 sites
Imperial College Healthcare NI-lS Trust (200)
London, W68RF
Re:Cognition Health Ltd (202)
London, WlG9JF
Re:Cognition Health Ltd (205)
Plymouth, Devon, PL68BT
About this study
Official title: An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.
Read the detailed description
This is a 9-month, multicenter open-label safety extension study. Participants who have successfully completed Study NCT03670953 [A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in Parkinson's Disease Patients with Motor Fluctuations] may have the opportunity to enroll in this open-label study.
- Conditions
- Parkinson Disease
- Being tested
- IPX203
- Keywords
- motor fluctuations, IPX203
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IPX203Drug
IPX203 extended release capsules
| Study group | Role | What they receive |
|---|---|---|
| Open Label IPX203 | Experimental | All participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety. Receives: Drug: IPX203 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-Emergent Adverse Events
An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was considered as treatment-emergent if the date of onset was on or after the date of the first open-label study drug administration in this Study IPX203-B16-03 and no later than 1 day after the last study drug dose in the study.
Measured: From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])
Secondary outcomes (28)
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).
Measured: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.
Measured: Baseline, Month 9/ET
Patient Global Impression of Severity (PGI-S)
The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Patient Global Impression of Severity (PGI-S)
The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.
Measured: Baseline, Month 9/ET
Percentage of Participants With a PGI-S ≥ 4 and PGI-S ≥ 5
The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Clinical Global Impression of Severity (CGI-S)
The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.
Measured: Baseline, Month 3, Month 6, Month 9/ET
Change From Baseline in Clinical Global Impression of Severity (CGI-S)
The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.
Measured: Baseline, Month 9/ET
Percentage of Participants With a CGI-S ≥ 4 and CGI-S ≥ 5
The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
39-item Parkinson's Disease Questionnaire (PDQ-39): Total
The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in PDQ-39: Total
The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Month 9/ET
Parkinson Anxiety Scale (PAS): Total
The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Parkinson Anxiety Scale (PAS): Total
The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.
Measured: Baseline, Month 9/ET
Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total
The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total
The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.
Measured: Baseline, Month 9/ET
Parkinson's Disease Sleep Scale-2 (PDSS-2) Total
The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.
Measured: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total
The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.
Measured: Baseline, Month 9/ET
Treatment Satisfaction Assessment (TSA)
The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.
Measured: Month 3, Month 6 and Month 9/ET
Percentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral)
The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.
Measured: Month 3, Month 6, and Month 9/ET
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2019
- Study start3 Apr 2019
- Primary completion21 Mar 2022
- Study completion21 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 419 participants (actual)
Sponsor and investigators
- Lead sponsor
- Impax Laboratories, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Impax Impax Study Director, Study director, Impax Laboratories, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03877510
- Sponsor's protocol ID
- IPX203-B16-03
- Other IDs
- 2018-002234-21, 2018
- Status last verified
- Jun 2023
- First submitted
- 12 Mar 2019
- Last updated
- 13 Jul 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations
- ClinicalTrials.gov ID
- NCT03877510
- Acronym / sponsor ID
- IPX203-B16-03
- Conditions
- Parkinson Disease
- Keywords
- motor fluctuations, IPX203
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 419 participants (actual)
- Lead sponsor
- Impax Laboratories, LLCIndustry (pharma, biotech, devices)
- Study start
- 3 Apr 2019 (actual)
- Primary completion
- 21 Mar 2022 (actual)
- Study completion
- 21 Mar 2022 (actual)
- First posted
- 15 Mar 2019 (actual)
- Results
- Posted 6 Jun 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.
Detailed description
This is a 9-month, multicenter open-label safety extension study. Participants who have successfully completed Study NCT03670953 [A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in Parkinson's Disease Patients with Motor Fluctuations] may have the opportunity to enroll in this open-label study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Open Label IPX203 | Experimental | Drug: IPX203All participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Successfully completed Study IPX203-B16-02
- Able to provide written informed consent prior to the conduct of any study-specific procedures.
- Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit (Visit 1).
- Agrees to use a medically acceptable method of contraception throughout the study and for 6 weeks after completing the study.
Key exclusion criteria (4 listed)
- Intends to use any doses of Rytary® or Duopa™ during this study.
- Plans to use an investigational treatment other than IPX203 during the course of this study.
- Neurosurgical ablation treatment for PD is planned or anticipated during the study period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study.
- Participants who, in the opinion of the clinical investigator, should not participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IPX203IPX203 extended release capsules | Drug | Open Label IPX203 |
Primary outcome
Number of Participants With Treatment-Emergent Adverse Events
Time frame: From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])
An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was considered as treatment-emergent if the date of onset was on or after the date of the first open-label study drug administration in this Study IPX203-B16-03 and no later than 1 day after the last study drug dose in the study.
28 secondary outcomes
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total
Time frame: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I
Time frame: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II
Time frame: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III
Time frame: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV
Time frame: Baseline, Month 9/ET
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III
Time frame: Baseline, Month 9/ET
Patient Global Impression of Severity (PGI-S)
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Patient Global Impression of Severity (PGI-S)
Time frame: Baseline, Month 9/ET
Percentage of Participants With a PGI-S ≥ 4 and PGI-S ≥ 5
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Clinical Global Impression of Severity (CGI-S)
Time frame: Baseline, Month 3, Month 6, Month 9/ET
Change From Baseline in Clinical Global Impression of Severity (CGI-S)
Time frame: Baseline, Month 9/ET
Percentage of Participants With a CGI-S ≥ 4 and CGI-S ≥ 5
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
39-item Parkinson's Disease Questionnaire (PDQ-39): Total
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in PDQ-39: Total
Time frame: Baseline, Month 9/ET
Parkinson Anxiety Scale (PAS): Total
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Parkinson Anxiety Scale (PAS): Total
Time frame: Baseline, Month 9/ET
Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total
Time frame: Baseline, Month 9/ET
Parkinson's Disease Sleep Scale-2 (PDSS-2) Total
Time frame: Baseline, Month 3, Month 6, and Month 9/ET
Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total
Time frame: Baseline, Month 9/ET
Treatment Satisfaction Assessment (TSA)
Time frame: Month 3, Month 6 and Month 9/ET
Percentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral)
Time frame: Month 3, Month 6, and Month 9/ET
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Impax Impax Study Director study director
Impax Laboratories, LLC
98 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing IPX203 in people with Parkinson Disease, run by Impax Laboratories, LLC at 98 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 98 sites in United States, Spain, Italy, Poland, Czechia and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Jun 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment-Emergent Adverse Events (time frame: From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2023.